Decoy Therapeutics Inc. (DCOY) Stock Score, Valuation & Financial Research

Decoy Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for DCOY

Decoy Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.97. These figures are a research snapshot, not a buy or sell recommendation.

What Decoy Therapeutics Inc. does

Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Decoy Therapeutics Inc. is a clinical-stage biotechnology company focused on the development of novel therapeutic drug modalities, specifically peptide conjugates. The company operates as a research and development entity and does not currently generate revenue from product sales, relying instead on capital raises and financing activities to fund its operations and clinical pipeline.

Products and services

  • The company is focused on the development of peptide conjugates as a therapeutic drug modality for various medical conditions.

Business strengths to evaluate

  • Development of emerging peptide conjugate therapeutic modalities Source

Business risks and research considerations

  • History of operating losses and dependence on future financing Source
  • Risks associated with clinical development and regulatory approval processes Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

DCOY financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.97
Market capitalization:
1.05M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -14.45M
Free cash flow:
USD -4.83M
Cash:
USD 8.29M
Total debt:
USD 0.00
EPS:
USD -29.09

What stands out

  • Free cash flow is USD -4.83M, negative for the stored period.
  • The balance sheet shows USD 8.29M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 8.29M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for DCOY

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can DCOY fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is DCOY likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for DCOY to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of DCOY's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research DCOY

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.